Stem-cell board too close to industry, critics worry
By San Jose Mercury News,
San Jose Mercury News
| 05. 19. 2005
California's new stem-cell institute is poised to begin spending $3 billion in public money for research, but watchdogs are worried about whether the board can distribute the money free of industry influence.
Critics say some of those on the institute's governing board have ties or even personal investments in business or other organizations that could benefit from the money. In addition, the institute's newly approved conflict-of-interest rules are inconsistent and largely self-policing, according to the critics. For instance, board members applied stricter rules to the institute's staff than themselves.
As a result, a panel of state lawmakers today is expected to vote on a proposal that would toughen the institute's conflict-of-interest provisions. It would require the institute's board, employees and science advisers to divest their holdings in firms conducting stem-cell or other biomedical work.
Their bill, SCA 13, backed by a state Senate committee last month, is based on similar rules established by the National Institutes of Health. But the NIH policies themselves are under fire as too draconian and may be softened considerably.
The fact is, there is little...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...